cefepime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 535 88040-23-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefepime dihydrochloride hydrate
  • cefepime
  • cefepime hydrochloride
  • cefimen
  • tsefepim
  • cefepime HCl
A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.
  • Molecular weight: 480.56
  • Formula: C19H24N6O5S2
  • CLOGP: -4.87
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 2
  • TPSA: 150.04
  • ALOGS: -4.49
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 18, 1996 FDA HOSPIRA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 369.76 18.17 183 14009 33528 50557404
Acute kidney injury 296.41 18.17 341 13851 227717 50363215
Febrile neutropenia 262.88 18.17 218 13974 97449 50493483
Neurotoxicity 188.57 18.17 89 14103 14651 50576281
Status epilepticus 177.83 18.17 83 14109 13323 50577609
Sepsis 141.42 18.17 180 14012 132745 50458187
Myoclonus 136.42 18.17 71 14121 14399 50576533
Drug reaction with eosinophilia and systemic symptoms 136.37 18.17 90 14102 28334 50562598
Cytokine release syndrome 131.93 18.17 59 14133 8575 50582357
Pyrexia 130.03 18.17 311 13881 379892 50211040
Multiple organ dysfunction syndrome 120.10 18.17 105 14087 50232 50540700
Septic shock 99.33 18.17 100 14092 57075 50533857
Thrombocytopenia 98.28 18.17 148 14044 127525 50463407
Tubulointerstitial nephritis 95.13 18.17 57 14135 15154 50575778
Toxic encephalopathy 88.47 18.17 39 14153 5476 50585456
Mental status changes 87.17 18.17 76 14116 36196 50554736
Respiratory failure 85.27 18.17 116 14076 91065 50499867
Pain 84.03 18.17 29 14163 578874 50012058
Clostridium difficile colitis 68.12 18.17 49 14143 17693 50573239
Pneumonia 66.79 18.17 245 13947 378156 50212776
Arthralgia 65.28 18.17 21 14171 438681 50152251
Klebsiella infection 64.09 18.17 34 14158 7160 50583772
Neutrophil count decreased 63.07 18.17 71 14121 45955 50544977
Fatigue 60.41 18.17 66 14126 707535 49883397
Platelet count decreased 60.00 18.17 104 14088 100622 50490310
Drug resistance 58.57 18.17 46 14146 18943 50571989
Renal tubular necrosis 58.17 18.17 36 14156 10132 50580800
Pathogen resistance 56.73 18.17 29 14163 5660 50585272
Neutropenia 55.70 18.17 126 14066 147839 50443093
Alopecia 53.50 18.17 4 14188 245043 50345889
Hypoxia 52.29 18.17 68 14124 51055 50539877
Acute generalised exanthematous pustulosis 49.50 18.17 31 14161 8907 50582025
Mixed liver injury 47.71 18.17 22 14170 3429 50587503
Abdominal discomfort 47.27 18.17 5 14187 231636 50359296
Cytomegalovirus test positive 47.03 18.17 20 14172 2572 50588360
Drug intolerance 46.64 18.17 4 14188 219100 50371832
Headache 44.52 18.17 46 14146 506489 50084443
Immune effector cell-associated neurotoxicity syndrome 42.93 18.17 15 14177 1135 50589797
Nasopharyngitis 42.52 18.17 3 14189 192924 50398008
Fungaemia 41.47 18.17 17 14175 1995 50588937
Bacteraemia 40.32 18.17 33 14159 14400 50576532
Rheumatoid arthritis 39.75 18.17 5 14187 202545 50388387
Aspartate aminotransferase increased 39.39 18.17 75 14117 77923 50513009
Malaise 38.87 18.17 23 14169 335509 50255423
Acute respiratory distress syndrome 38.62 18.17 38 14154 21061 50569871
Clostridium difficile infection 37.87 18.17 41 14151 25398 50565534
Nephropathy toxic 37.45 18.17 25 14167 8004 50582928
Renal impairment 36.06 18.17 71 14121 75590 50515342
Confusional state 35.75 18.17 124 14068 185804 50405128
Pancytopenia 35.49 18.17 75 14117 83955 50506977
Trichosporon infection 34.77 18.17 9 14183 241 50590691
Hypotension 34.52 18.17 144 14048 235325 50355607
Antibiotic level above therapeutic 34.42 18.17 9 14183 251 50590681
Respiratory distress 33.44 18.17 42 14150 30447 50560485
Nephritis allergic 33.42 18.17 8 14184 154 50590778
Dizziness 33.25 18.17 29 14163 346340 50244592
Shock 32 18.17 34 14158 20616 50570316
Renal failure 31.73 18.17 83 14109 106550 50484382
Toxic epidermal necrolysis 31.54 18.17 34 14158 20958 50569974
Metabolic encephalopathy 31.51 18.17 19 14173 5102 50585830
Hepatic function abnormal 31.14 18.17 42 14150 32639 50558293
Enterococcal infection 31.03 18.17 21 14171 6877 50584055
White blood cell count decreased 30.88 18.17 87 14105 116635 50474297
Enterococcal bacteraemia 30.68 18.17 12 14180 1246 50589686
Product dose omission issue 30.65 18.17 7 14185 183831 50407101
Differentiation syndrome 30.39 18.17 11 14181 922 50590010
Peripheral swelling 30.30 18.17 10 14182 205926 50385006
Dysbiosis 30.08 18.17 10 14182 650 50590282
Toxic skin eruption 29.92 18.17 25 14167 11226 50579706
Hypertensive heart disease 29.91 18.17 14 14178 2256 50588676
Alanine aminotransferase increased 29.66 18.17 72 14120 88287 50502645
Pseudomonas infection 29.41 18.17 23 14169 9407 50581525
Anaemia 29.22 18.17 144 14048 252312 50338620
Bronchopulmonary aspergillosis 29.21 18.17 21 14171 7571 50583361
Weight decreased 28.81 18.17 13 14179 221232 50369700
Blood creatinine increased 28.77 18.17 65 14127 76095 50514837
Mucormycosis 28.72 18.17 14 14178 2469 50588463
Leukocytosis 27.84 18.17 33 14159 22546 50568386
Therapeutic product effect decreased 27.57 18.17 3 14189 136047 50454885
Sinusitis 27.44 18.17 7 14185 170551 50420381
Acute respiratory failure 27.44 18.17 37 14155 28745 50562187
Klebsiella bacteraemia 27.03 18.17 11 14181 1266 50589666
Systemic lupus erythematosus 26.33 18.17 4 14188 140618 50450314
Acute graft versus host disease in skin 26.13 18.17 14 14178 3004 50587928
Eosinophilia 25.92 18.17 29 14163 18623 50572309
Graft versus host disease 25.91 18.17 18 14174 6148 50584784
Eosinophilic pneumonia 25.89 18.17 12 14180 1892 50589040
Swelling 25.85 18.17 12 14180 200860 50390072
Cholestatic liver injury 25.20 18.17 12 14180 2009 50588923
Rash maculo-papular 25.02 18.17 34 14158 26607 50564325
Hyperoxaluria 24.57 18.17 6 14186 126 50590806
Agranulocytosis 24.27 18.17 30 14162 21391 50569541
Stenotrophomonas infection 24.20 18.17 11 14181 1658 50589274
Chemotherapeutic drug level increased 24.17 18.17 6 14186 135 50590797
Leukopenia 23.70 18.17 56 14136 67472 50523460
Acute myeloid leukaemia 23.68 18.17 25 14167 15049 50575883
Aphasia 23.25 18.17 34 14158 28460 50562472
Hypersensitivity 23.17 18.17 16 14176 215145 50375787
Neutropenic colitis 23.17 18.17 12 14180 2405 50588527
Engraft failure 22.97 18.17 7 14185 343 50590589
Hyperbilirubinaemia 22.86 18.17 20 14172 9550 50581382
Cytomegalovirus viraemia 22.78 18.17 15 14177 4694 50586238
Gait disturbance 22.56 18.17 7 14185 149998 50440934
Cholestasis 21.73 18.17 31 14161 25370 50565562
Pseudomembranous colitis 21.57 18.17 12 14180 2773 50588159
Disseminated intravascular coagulation 21.05 18.17 25 14167 17110 50573822
Hypoaesthesia 20.90 18.17 5 14187 127252 50463680
Ileus 20.88 18.17 22 14170 13207 50577725
Fall 20.76 18.17 39 14153 334893 50256039
Enterococcal sepsis 20.39 18.17 9 14183 1266 50589666
Encephalitis Japanese B 20.29 18.17 4 14188 29 50590903
Respiratory alkalosis 19.91 18.17 11 14181 2508 50588424
Tonsillitis bacterial 19.84 18.17 5 14187 120 50590812
Laryngeal inflammation 19.38 18.17 5 14187 132 50590800
Musculoskeletal stiffness 19.31 18.17 6 14186 128475 50462457
Angiokeratoma 19.24 18.17 5 14187 136 50590796
Weight increased 19.22 18.17 17 14175 201874 50389058
Electrocardiogram T wave alternans 18.96 18.17 4 14188 42 50590890
Staphylococcal infection 18.90 18.17 35 14157 35581 50555351
Systemic candida 18.86 18.17 11 14181 2779 50588153
Lymphatic disorder 18.69 18.17 6 14186 349 50590583
Activated partial thromboplastin time prolonged 18.64 18.17 15 14177 6387 50584545
Muscle spasms 18.62 18.17 6 14186 125547 50465385
Mucosal inflammation 18.31 18.17 37 14155 40105 50550827
Thrombotic microangiopathy 18.30 18.17 17 14175 8774 50582158
Subdiaphragmatic abscess 18.25 18.17 4 14188 51 50590881

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 230.30 16.18 176 18529 30867 29524955
Acute kidney injury 198.19 16.18 483 18222 264784 29291038
Febrile neutropenia 165.45 16.18 272 18433 111968 29443854
Neurotoxicity 149.99 16.18 101 18604 14512 29541310
Cytokine release syndrome 147.55 16.18 96 18609 13023 29542799
Septic shock 102.10 16.18 159 18546 62401 29493421
Drug reaction with eosinophilia and systemic symptoms 96.28 16.18 103 18602 27889 29527933
Multiple organ dysfunction syndrome 92.83 16.18 153 18552 62963 29492859
Respiratory failure 88.69 16.18 192 18513 96939 29458883
Pyrexia 83.65 16.18 381 18324 287241 29268581
Acute generalised exanthematous pustulosis 78.24 16.18 47 18658 5536 29550286
Fatigue 72.28 16.18 57 18648 316764 29239058
Tubulointerstitial nephritis 71.64 16.18 71 18634 17572 29538250
Hypoxia 71.17 16.18 116 18589 47263 29508559
Clostridium difficile colitis 70.69 16.18 62 18643 13150 29542672
Renal tubular necrosis 68.35 16.18 63 18642 14252 29541570
Sepsis 64.07 16.18 217 18488 142465 29413357
Myoclonus 62.43 16.18 58 18647 13251 29542571
Pathogen resistance 62.26 16.18 47 18658 8069 29547753
Neutrophil count decreased 57.89 16.18 101 18604 43466 29512356
Mental status changes 57.23 16.18 89 18616 34838 29520984
Methaemoglobinaemia 55.16 16.18 29 18676 2642 29553180
Neutropenia 52.79 16.18 193 18512 131518 29424304
Dizziness 51.46 16.18 28 18677 189656 29366166
Enterococcal infection 50.77 16.18 42 18663 8226 29547596
Product dose omission issue 49.02 16.18 3 18702 96380 29459442
Immune effector cell-associated neurotoxicity syndrome 47.79 16.18 22 18683 1502 29554320
Death 46.10 16.18 92 18613 341992 29213830
Brain herniation 44.32 16.18 28 18677 3605 29552217
Meningitis candida 42.79 16.18 10 18695 71 29555751
Disseminated intravascular coagulation 41.56 16.18 57 18648 19923 29535899
Nephropathy toxic 41.29 16.18 42 18663 10714 29545108
Status epilepticus 41.17 16.18 42 18663 10752 29545070
Haemodialysis 40.29 16.18 40 18665 9914 29545908
Myocardial infarction 38.53 16.18 11 18694 110285 29445537
Bacteraemia 36.13 16.18 48 18657 16275 29539547
Pseudomonas infection 35.65 16.18 39 18666 10813 29545009
Botulism 35.44 16.18 10 18695 160 29555662
Systemic candida 35.36 16.18 22 18683 2758 29553064
Platelet count decreased 35.05 16.18 145 18560 104527 29451295
Glomerulosclerosis 34.42 16.18 14 18691 706 29555116
Drug resistance 34.04 16.18 54 18651 21486 29534336
Blood culture positive 33.98 16.18 26 18679 4551 29551271
Thrombocytopenia 33.46 16.18 171 18534 134652 29421170
Fall 33.11 16.18 38 18667 177140 29378682
Antibiotic level above therapeutic 32.89 16.18 10 18695 210 29555612
Immune thrombocytopenia 32.52 16.18 32 18673 7845 29547977
Bronchopulmonary aspergillosis 31.57 16.18 39 18666 12305 29543517
Uraemic encephalopathy 30.69 16.18 10 18695 265 29555557
Clostridium difficile infection 30.52 16.18 44 18661 16097 29539725
Aspergillus infection 29.62 16.18 35 18670 10546 29545276
Confusional state 29.52 16.18 159 18546 127718 29428104
Cytomegalovirus enterocolitis 29.51 16.18 13 18692 800 29555022
Arthralgia 29.41 16.18 27 18678 139590 29416232
Depression 28.81 16.18 9 18696 85138 29470684
Disseminated mucormycosis 28.44 16.18 10 18695 336 29555486
White blood cell count decreased 28.30 16.18 116 18589 83246 29472576
Candida infection 28.06 16.18 41 18664 15184 29540638
Aspartate aminotransferase increased 27.75 16.18 92 18613 59633 29496189
Eosinophilia 27.64 16.18 50 18655 22111 29533711
Pleural effusion 27.59 16.18 104 18601 71804 29484018
Metabolic encephalopathy 27.50 16.18 21 18684 3666 29552156
Burkholderia test positive 26.95 16.18 13 18692 986 29554836
Cytomegalovirus viraemia 26.70 16.18 26 18679 6294 29549528
Malaise 25.93 16.18 38 18667 159564 29396258
Enterocolitis 25.53 16.18 26 18679 6640 29549182
Weight decreased 25.43 16.18 35 18670 150870 29404952
Acute respiratory distress syndrome 25.18 16.18 49 18656 22886 29532936
Klebsiella infection 25.17 16.18 27 18678 7322 29548500
Rash morbilliform 25.01 16.18 17 18688 2476 29553346
Acute myeloid leukaemia recurrent 24.97 16.18 15 18690 1765 29554057
Pain 24.86 16.18 44 18661 171388 29384434
Transaminases increased 24.38 16.18 48 18657 22614 29533208
Gait disturbance 24.37 16.18 8 18697 73341 29482481
Insomnia 24.17 16.18 13 18692 88748 29467074
Septic embolus 23.40 16.18 12 18693 1038 29554784
Toxic encephalopathy 23.38 16.18 21 18684 4591 29551231
Mucormycosis 23.26 16.18 22 18683 5136 29550686
Cholestasis 23.22 16.18 48 18657 23414 29532408
Respiratory distress 23.22 16.18 58 18647 32048 29523774
Bacterial toxaemia 23.07 16.18 7 18698 146 29555676
Choluria 23.02 16.18 7 18698 147 29555675
Cytokine storm 22.83 16.18 10 18695 607 29555215
Corynebacterium infection 22.73 16.18 9 18696 423 29555399
Trichosporon infection 22.48 16.18 10 18695 630 29555192
Alanine aminotransferase increased 21.96 16.18 96 18609 70848 29484974
Renal failure 21.86 16.18 139 18566 118460 29437362
Pneumonia bacterial 21.48 16.18 28 18677 9315 29546507
Joint swelling 21.37 16.18 3 18702 49627 29506195
Blood pressure increased 21.31 16.18 10 18695 73793 29482029
Fungal infection 21.19 16.18 34 18671 13651 29542171
Dyspnoea 21.08 16.18 121 18584 326611 29229211
Hypersensitivity vasculitis 20.95 16.18 17 18688 3240 29552582
Kidney fibrosis 20.63 16.18 14 18691 2033 29553789
Cerebral aspergillosis 20.52 16.18 12 18693 1344 29554478
Acute lymphocytic leukaemia recurrent 20.25 16.18 15 18690 2501 29553321
Vanishing bile duct syndrome 20.05 16.18 9 18696 579 29555243
Anxiety 19.82 16.18 15 18690 85350 29470472
Feeling abnormal 19.81 16.18 5 18700 54440 29501382
Hospitalisation 19.29 16.18 3 18702 45985 29509837
Headache 19.16 16.18 52 18653 173955 29381867
Blood creatinine increased 19.06 16.18 105 18600 84997 29470825
Toxic epidermal necrolysis 18.98 16.18 38 18667 18115 29537707
Aphasia 18.67 16.18 39 18666 19159 29536663
Drug intolerance 18.48 16.18 4 18701 48375 29507447
Inappropriate schedule of product administration 18.43 16.18 3 18702 44469 29511353
Procalcitonin increased 18.41 16.18 12 18693 1630 29554192
Systemic mycosis 18.19 16.18 11 18694 1310 29554512
Drug level increased 18.08 16.18 38 18667 18749 29537073
Eye infection fungal 17.90 16.18 7 18698 318 29555504
Peripheral swelling 17.84 16.18 9 18696 63730 29492092
Sputum culture positive 17.70 16.18 12 18693 1740 29554082
Retinal ischaemia 17.68 16.18 7 18698 329 29555493
Flavobacterium infection 17.66 16.18 5 18700 81 29555741
Hepatosplenic candidiasis 17.20 16.18 6 18699 197 29555625
Asthenia 17.13 16.18 74 18631 215176 29340646
Hypercapnia 17.01 16.18 16 18689 3710 29552112
Dysbiosis 16.53 16.18 7 18698 391 29555431
Liver abscess 16.53 16.18 15 18690 3323 29552499
Staphylococcal sepsis 16.52 16.18 24 18681 8838 29546984
Adenoviral haemorrhagic cystitis 16.45 16.18 7 18698 396 29555426
Gastrointestinal mucormycosis 16.27 16.18 5 18700 109 29555713

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 536.77 16.12 340 30532 58479 64409381
Acute kidney injury 440.10 16.12 776 30096 448464 64019396
Febrile neutropenia 352.56 16.12 441 30431 187216 64280644
Neurotoxicity 318.19 16.12 185 30687 27219 64440641
Cytokine release syndrome 272.40 16.12 152 30720 20677 64447183
Drug reaction with eosinophilia and systemic symptoms 206.70 16.12 186 30686 54031 64413829
Status epilepticus 194.28 16.12 124 30748 21539 64446321
Septic shock 180.61 16.12 237 30635 105200 64362660
Myoclonus 175.25 16.12 123 30749 24995 64442865
Pyrexia 173.42 16.12 623 30249 558021 63909839
Multiple organ dysfunction syndrome 166.06 16.12 223 30649 101190 64366670
Sepsis 164.34 16.12 349 30523 229992 64237868
Tubulointerstitial nephritis 152.49 16.12 123 30749 30786 64437074
Respiratory failure 147.24 16.12 271 30601 160912 64306948
Mental status changes 139.60 16.12 159 30713 61003 64406857
Renal tubular necrosis 128.61 16.12 97 30775 22013 64445847
Thrombocytopenia 124.01 16.12 307 30565 223494 64244366
Fatigue 118.28 16.12 111 30761 748619 63719241
Neutrophil count decreased 114.65 16.12 162 30710 77034 64390826
Clostridium difficile colitis 112.88 16.12 98 30774 27125 64440735
Hypoxia 112.17 16.12 172 30700 87977 64379883
Pain 109.26 16.12 65 30807 553446 63914414
Platelet count decreased 100.25 16.12 237 30635 167474 64300386
Neutropenia 99.86 16.12 296 30576 239328 64228532
Arthralgia 99.02 16.12 44 30828 442216 64025644
Pathogen resistance 98.28 16.12 66 30806 12477 64455383
Drug resistance 93.50 16.12 99 30773 35003 64432857
Toxic encephalopathy 90.01 16.12 57 30815 9758 64458102
Dizziness 89.88 16.12 47 30825 430116 64037744
Immune effector cell-associated neurotoxicity syndrome 89.85 16.12 37 30835 2558 64465302
Joint swelling 83.12 16.12 5 30867 215377 64252483
Acute generalised exanthematous pustulosis 80.25 16.12 61 30811 13997 64453863
Enterococcal infection 78.79 16.12 60 30812 13806 64454054
Klebsiella infection 76.63 16.12 58 30814 13223 64454637
Headache 76.03 16.12 85 30787 529382 63938478
Nephropathy toxic 72.50 16.12 63 30809 17451 64450409
Product dose omission issue 70.88 16.12 6 30866 194741 64273119
Malaise 69.39 16.12 53 30819 396194 64071666
Pneumonia 65.68 16.12 475 30397 559101 63908759
Drug intolerance 65.22 16.12 7 30865 187985 64279875
Bacteraemia 63.13 16.12 71 30801 26840 64441020
Rheumatoid arthritis 59.95 16.12 5 30867 164289 64303571
Clostridium difficile infection 59.84 16.12 80 30792 36083 64431777
Disseminated intravascular coagulation 58.87 16.12 75 30797 32273 64435587
White blood cell count decreased 58.24 16.12 187 30685 157650 64310210
Confusional state 57.20 16.12 262 30610 260882 64206978
Renal failure 57.12 16.12 204 30668 181484 64286376
Antibiotic level above therapeutic 56.40 16.12 18 30854 595 64467265
Fall 55.42 16.12 71 30801 416755 64051105
Nasopharyngitis 55.26 16.12 13 30859 196060 64271800
Methaemoglobinaemia 54.83 16.12 31 30841 4317 64463543
Aspartate aminotransferase increased 54.66 16.12 153 30719 119635 64348225
Trichosporon infection 53.55 16.12 19 30853 873 64466987
Alopecia 53.04 16.12 8 30864 165682 64302178
Metabolic encephalopathy 52.95 16.12 38 30834 7987 64459873
Acute respiratory distress syndrome 52.36 16.12 78 30794 38857 64429003
Pseudomonas infection 52.22 16.12 53 30819 17830 64450030
Peripheral swelling 51.33 16.12 18 30854 209135 64258725
Bronchopulmonary aspergillosis 51.12 16.12 54 30818 19031 64448829
Haemodialysis 50.58 16.12 51 30821 17026 64450834
Pancytopenia 49.46 16.12 166 30706 143143 64324717
Mucormycosis 48.98 16.12 35 30837 7306 64460554
Eosinophilia 47.97 16.12 74 30798 38002 64429858
Brain herniation 47.90 16.12 33 30839 6500 64461360
Weight decreased 47.74 16.12 40 30832 285699 64182161
Blood creatinine increased 47.49 16.12 158 30714 135624 64332236
Arthropathy 46.07 16.12 3 30869 120964 64346896
Abdominal discomfort 44.21 16.12 16 30856 182306 64285554
Gait disturbance 43.66 16.12 14 30858 172141 64295719
Pleural effusion 43.13 16.12 146 30726 126413 64341447
Cholestasis 42.84 16.12 77 30795 44795 64423065
Respiratory distress 42.75 16.12 84 30788 52247 64415613
Toxic epidermal necrolysis 42.36 16.12 69 30803 37097 64430763
Alanine aminotransferase increased 41.89 16.12 154 30718 138877 64328983
Systemic candida 41.65 16.12 28 30844 5301 64462559
Dyspnoea 41.60 16.12 190 30682 718484 63749376
Myocardial infarction 41.15 16.12 14 30858 165807 64302053
Cytomegalovirus viraemia 40.93 16.12 37 30835 10791 64457069
Meningitis candida 39.98 16.12 10 30862 132 64467728
Fungaemia 39.83 16.12 24 30848 3761 64464099
Pain in extremity 38.84 16.12 53 30819 303032 64164828
Depression 38.24 16.12 20 30852 183271 64284589
Neutropenic colitis 38.05 16.12 25 30847 4556 64463304
Enterocolitis 37.64 16.12 37 30835 11981 64455879
Hypotension 36.05 16.12 308 30564 380666 64087194
Acute respiratory failure 35.86 16.12 76 30796 49858 64418002
Differentiation syndrome 35.32 16.12 18 30854 2036 64465824
Septic embolus 34.91 16.12 17 30855 1745 64466115
Agranulocytosis 34.47 16.12 64 30808 38165 64429695
Aphasia 33.82 16.12 66 30806 40840 64427020
Musculoskeletal stiffness 33.09 16.12 9 30863 123197 64344663
Blood pressure increased 32.90 16.12 21 30851 172531 64295329
Cholestatic liver injury 32.82 16.12 21 30851 3658 64464202
Cytomegalovirus enterocolitis 32.77 16.12 15 30857 1340 64466520
Insomnia 32.65 16.12 28 30844 197808 64270052
Liver abscess 32.56 16.12 24 30848 5256 64462604
Hypoaesthesia 32.39 16.12 13 30859 139095 64328765
Immune thrombocytopenia 32.38 16.12 38 30834 15028 64452832
Enterococcal bacteraemia 31.96 16.12 18 30854 2487 64465373
Blood culture positive 31.95 16.12 28 30844 7840 64460020
Blood bilirubin increased 31.82 16.12 79 30793 57474 64410386
Pulmonary haemorrhage 31.45 16.12 35 30837 13074 64454786
Rash morbilliform 30.87 16.12 23 30849 5118 64462742
Glomerulosclerosis 30.85 16.12 13 30859 952 64466908
Uraemic encephalopathy 30.82 16.12 11 30861 514 64467346
Botulism 30.76 16.12 10 30862 351 64467509
Feeling abnormal 30.28 16.12 13 30859 133589 64334271
Candida infection 30.10 16.12 54 30818 31365 64436495
Nausea 29.98 16.12 237 30635 785563 63682297
Renal impairment 29.90 16.12 136 30736 134881 64332979
Weight increased 29.71 16.12 35 30837 213313 64254547
Mixed liver injury 29.56 16.12 23 30849 5458 64462402
Arthritis 29.36 16.12 3 30869 83811 64384049
Enterococcal sepsis 29.35 16.12 17 30855 2477 64465383
Haemophagocytic lymphohistiocytosis 29.19 16.12 39 30833 17570 64450290
Pneumonia bacterial 29.17 16.12 36 30836 14999 64452861
Tumour lysis syndrome 29.13 16.12 41 30831 19399 64448461
Cytomegalovirus test positive 28.65 16.12 22 30850 5122 64462738
Acute myeloid leukaemia 28.64 16.12 49 30823 27414 64440446
Muscle spasms 28.51 16.12 16 30856 141007 64326853
Injection site pain 28.34 16.12 9 30863 111399 64356461
Hepatic function abnormal 28.19 16.12 81 30791 64232 64403628
Drug level increased 28.05 16.12 55 30817 34141 64433719
Off label use 27.88 16.12 441 30431 632365 63835495
Leukocytosis 27.75 16.12 58 30814 37682 64430178
Asthma 27.44 16.12 6 30866 95219 64372641
Disseminated mucormycosis 27.41 16.12 10 30862 498 64467362
Aspergillus infection 26.73 16.12 36 30836 16343 64451517
Staphylococcal infection 25.36 16.12 67 30805 50611 64417249
Lower respiratory tract infection 25.24 16.12 7 30865 94607 64373253
Nephritis allergic 25.04 16.12 10 30862 638 64467222
Sinusitis 24.88 16.12 20 30852 145908 64321952
Bacterial toxaemia 24.56 16.12 7 30865 156 64467704
Transaminases increased 24.42 16.12 61 30811 44533 64423327
Anxiety 24.40 16.12 37 30835 202612 64265248
Corynebacterium infection 24.25 16.12 11 30861 962 64466898
Activated partial thromboplastin time prolonged 23.74 16.12 30 30842 12801 64455059
Drug eruption 23.67 16.12 53 30819 36083 64431777
Graft versus host disease 23.52 16.12 31 30841 13782 64454078
Hypersensitivity 23.52 16.12 36 30836 196416 64271444
Enterobacter infection 23.24 16.12 17 30855 3679 64464181
Pseudomembranous colitis 23.04 16.12 19 30853 4897 64462963
Delirium 22.83 16.12 79 30793 69115 64398745
Burkholderia test positive 22.60 16.12 9 30863 570 64467290
Systemic mycosis 22.58 16.12 14 30858 2309 64465551
Klebsiella bacteraemia 22.48 16.12 14 30858 2326 64465534
Gastrooesophageal reflux disease 22.46 16.12 6 30866 83137 64384723
Paraesthesia 22.23 16.12 19 30853 134503 64333357
Blood urea increased 21.71 16.12 58 30814 44095 64423765
Procalcitonin increased 21.68 16.12 14 30858 2477 64465383
Discomfort 21.54 16.12 6 30866 80872 64386988
Swelling 21.54 16.12 27 30845 160191 64307669
Contusion 21.54 16.12 14 30858 113951 64353909
Lung infiltration 21.42 16.12 37 30835 20852 64447008
Vanishing bile duct syndrome 21.41 16.12 11 30861 1266 64466594
Asthenia 21.35 16.12 119 30753 427925 64039935
Back pain 21.25 16.12 56 30816 250115 64217745
Cerebral aspergillosis 21.16 16.12 12 30860 1681 64466179
Pulseless electrical activity 20.79 16.12 28 30844 12711 64455149
Unresponsive to stimuli 20.68 16.12 62 30810 50331 64417529
Rash maculo-papular 20.39 16.12 59 30813 46967 64420893
Respiratory alkalosis 20.26 16.12 16 30856 3881 64463979
Leukopenia 20.23 16.12 99 30773 101143 64366717
Acidosis 20.22 16.12 33 30839 17762 64450098
Memory impairment 19.95 16.12 8 30864 85674 64382186
Mediastinitis 19.70 16.12 9 30863 800 64467060
Shock 19.58 16.12 51 30821 38189 64429671
Escherichia bacteraemia 19.51 16.12 18 30854 5385 64462475
Small intestinal obstruction 19.44 16.12 38 30834 23535 64444325
Choluria 19.36 16.12 7 30865 340 64467520
Serum ferritin increased 19.27 16.12 22 30850 8446 64459414
Chemotherapeutic drug level increased 19.26 16.12 7 30865 345 64467515
Chest pain 19.16 16.12 54 30818 235926 64231934
Death 19.09 16.12 144 30728 482561 63985299
Device related infection 19.04 16.12 44 30828 30582 64437278
Laryngeal inflammation 19.01 16.12 6 30866 191 64467669
Product contamination microbial 18.95 16.12 9 30863 874 64466986
Cytokine storm 18.91 16.12 9 30863 878 64466982
Vision blurred 18.61 16.12 10 30862 90306 64377554
Vertigo 18.53 16.12 3 30869 59008 64408852
Hyperbilirubinaemia 18.49 16.12 35 30837 21170 64446690
Systemic lupus erythematosus 18.48 16.12 7 30865 77605 64390255
Hypertensive heart disease 18.46 16.12 15 30857 3789 64464071
Flavobacterium infection 18.44 16.12 5 30867 92 64467768
Drug-induced liver injury 18.04 16.12 57 30815 47586 64420274
Dyspepsia 17.90 16.12 8 30864 80304 64387556
Blood lactate dehydrogenase increased 17.85 16.12 45 30827 33033 64434827
Mucosal inflammation 17.73 16.12 68 30804 62516 64405344
Acute lymphocytic leukaemia recurrent 17.71 16.12 15 30857 4011 64463849
Eye infection fungal 17.57 16.12 7 30865 444 64467416
Injection site erythema 17.51 16.12 6 30866 70794 64397066
Systemic inflammatory response syndrome 17.47 16.12 23 30849 10212 64457648
Dialysis 17.39 16.12 30 30842 16890 64450970
Ureaplasma infection 17.32 16.12 8 30864 730 64467130
Chest discomfort 17.30 16.12 18 30854 116088 64351772
Dry mouth 17.02 16.12 4 30868 60414 64407446
Sputum culture positive 16.98 16.12 13 30859 3013 64464847
Engraftment syndrome 16.98 16.12 9 30863 1104 64466756
Blastomycosis 16.95 16.12 7 30865 487 64467373
Kidney fibrosis 16.70 16.12 13 30859 3088 64464772
Abdominal pain upper 16.58 16.12 37 30835 174993 64292867
Tachypnoea 16.32 16.12 38 30834 26533 64441327
Venoocclusive liver disease 16.32 16.12 22 30850 9993 64457867
Osteoarthritis 16.32 16.12 5 30867 63331 64404529
Tonsillitis bacterial 16.26 16.12 5 30867 146 64467714
Lymphatic disorder 16.24 16.12 6 30866 310 64467550
Pneumonitis 16.18 16.12 57 30815 50308 64417552

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Fourth-generation cephalosporins
ATC J01RA06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection due to Pseudomonas aeruginosa indication 11218009
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Infectious disease of abdomen indication 128070006
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Bacterial peritonitis indication 197171003
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Urinary tract infection caused by Klebsiella indication 369001000119100
Complicated Proteus UTI indication
E. Coli Pyelonephritis indication
Complicated Urinary Tract Infections indication
Complicated Bacteroides Peritonitis indication
Complicated Streptococcus Peritonitis indication
Klebsiella Pyelonephritis indication
Complicated E. Coli Peritonitis indication
Enterobacter Pneumonia indication
Complicated Klebsiella Peritonitis indication
Proteus Pyelonephritis indication
Myoclonus contraindication 17450006
Colitis contraindication 64226004 DOID:0060180
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Disorder of brain contraindication 81308009 DOID:936
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.31 acidic
pKa3 3.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4024049 VUID
N0000022054 NUI
D01157 KEGG_DRUG
123171-59-5 SECONDARY_CAS_RN
20481 RXNORM
4020908 VANDF
4024049 VANDF
C0055003 UMLSCUI
CHEBI:478164 CHEBI
9WT PDB_CHEM_ID
CHEMBL186 ChEMBL_ID
CHEMBL1200962 ChEMBL_ID
D000077723 MESH_DESCRIPTOR_UI
DB01413 DRUGBANK_ID
10772 IUPHAR_LIGAND_ID
6092 INN_ID
807PW4VQE3 UNII
5479537 PUBCHEM_CID
116681 MMSL
4373 MMSL
d03882 MMSL
004974 NDDF
004975 NDDF
370370003 SNOMEDCT_US
370371004 SNOMEDCT_US
96048006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3193 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3193 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3195 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3195 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 30 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9566 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9735 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3222 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3223 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 29 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-130 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-131 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-240 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-241 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6144 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6144 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6145 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6145 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6147 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6147 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 63323-326 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 63323-340 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
CEFEPIME HUMAN PRESCRIPTION DRUG LABEL 1 66288-8100 INJECTION, POWDER, FOR SOLUTION 100 g INTRAVENOUS ANDA 18 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 66794-209 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 17 sections